Introduction
Human hematopoietic stem cells (HSC) have the potential to regenerate the entire hematopoietic system and are therefore attractive targets for gene therapy. The inability to efficiently transduce HSC in large animal models and humans has been a major hurdle to successful HSC gene therapy. The low gene transfer efficiency can at least in part be attributed to the fact that HSC are mostly in a quiescent state 1 and oncoretroviral vectors, which have been the most widely used vector system for HSC transduction, require mitosis for stable integration into the genome. 2, 3 A number of studies have shown that stimulation by cytokines is required for successful oncoretroviral transduction of HSC. [4] [5] [6] [7] However, prolonged cytokine-induced ex vivo expansion appears to significantly decrease the long-term repopulation ability of genemarked cells in nonhuman primates, 8 most likely due to a compromise of self-renewal capacity and engraftment potential of these cells. Thus, short culture/transduction protocols would be beneficial for most clinical applications.
Recent studies have suggested that the use of extended culture periods and stimulation with cytokines may not be necessary with lentiviral vectors. In contrast to oncoretroviral vectors, lentiviral vectors based on the human immunodeficiency virus (HIV) genome are able to transduce nondividing cells. 9, 10 In addition, the lentiviral preintegration complex is thought to be more stable than the oncoretroviral preintegration complex. 9, 11 Thus, it might be possible to introduce the lentiviral vector into stem cells during a brief ex vivo exposure and then reinfuse the cells into the myeloablated animal. The cells would then start to divide, and vector integration could take place during this early post-transplant time. Therefore, lentiviral vectors may be a more appropriate and potentially superior vector system than oncoretroviral vectors for transduction of HSC, especially in short transduction protocols.
We have used nonhuman primates to study hematopoietic stem cell gene transfer. Nonhuman primates are excellent preclinical models, 8, [12] [13] [14] [15] [16] more closely resembling the biology and inherent limitations of human gene therapy than murine models. In the current study, we have therefore investigated the transduction of HSC by lentiviral vectors in a competitive repopulation assay in the baboon.
Results

Engraftment of transduced cells and follow-up
Five baboons were transplanted with transduced CD34-enriched autologous marrow cells to compare transduc-tion efficiency between an oncoretroviral and lentiviral vector using a competitive repopulation assay. Since the goal of our study was to compare lentiviral vectors with the best oncoretroviral vector system available, we chose GALV as an envelope for the oncoretroviral vector in four of these animals. In one animal we used VSV-G for both the oncoretroviral and lentiviral vector to control for potential differences due to the pseudotype. Four of the five animals received cells that were transduced in the presence of growth factors, and one of these animals received cells that were not exposed to growth factors in vitro. Because of the low gene transfer level with the oncoretroviral vector under these conditions (2-day transduction protocol), we used in one additional animal a more recently described cPPT-containing lentiviral vector to study lentiviral transduction efficiency in the absence of growth factors. Table 1 summarizes the experimental design for each animal. All animals except M99017 engrafted without delay after transplantation. Median time to neutrophil engraftment (ANC >500/l) was 17 days (range 14-31). Median follow-up is 36 weeks (range 5-55). Animals were tested for replication competent helper virus production as described in Materials and methods. All six baboons were negative for GALV envelope sequences. Serum of five out of six animals was tested for the p24 antigen. One animal died due to pulmonary complications before serum was obtained for helper virus detection. Analysis of peripheral blood samples in all baboons tested did not reveal detectable p24 antigen at any time points (data not shown) indicating the absence of helper-virus production.
Pretransplant analysis of hematopoietic progenitor cells revealed higher gene marking with oncoretroviral than with lentiviral vector
The results of the pretransplant gene transfer analyses are summarized in Table 1 . Four animals received CD34-enriched cells transduced in the presence of growth factors. In three of the four animals (animals F97059, 00040 and F98286) the oncoretroviral and lentiviral vectors Gene Therapy were pseudotyped with the GALV and VSV-G envelope, respectively. Gene transfer efficiency in these three animals was considerably higher with the oncoretroviral vector than with the lentiviral vector as determined by colony PCR (53 ± 11.4% versus 29.7 ± 5%, P = 0.02). In one of the four animals (A00065) that received cells transduced in the presence of growth factors, both the oncoretroviral and lentiviral vectors were pseudotyped with VSV-G. In this animal, pretransplant marking in progenitor cells appeared to be similar between the lentiviral vector and the oncoretroviral vector. Two animals received cells transduced in the absence of growth factors. In one of these animals (M99017), VSV-G-pseudotype lentiviral vector was compared with a GALV-pseudotype oncoretroviral vector. In the second animal (J99202) that received cells transduced in the absence of growth factors, a non-cPPT-containing lentiviral vector was compared with a cPPT-containing lentiviral vector. In vitro marking achieved by the cPPT-containing lentiviral vector was only marginally higher when compared with the non-cPPT-containing vector in the absence of growth factors.
Since toxicity of the VSV-G protein is a potential concern, it is noteworthy that there was no reduction in colony growth of the cells exposed to VSV-G-pseudotype vector relative to the cells exposed to GALV-pseudotype vector, suggesting that, at least at the level of colony forming cells, there was no toxic effect of VSV-G.
Lentiviral transduction of hematopoietic repopulating cells is most efficient in the presence of growth factors
Two animals were transplanted with cells transduced in the absence of recombinant growth factors. In one animal we compared a lentiviral vector with a GALV-pseudotype oncoretroviral vector (M99017), and in a second animal (J99202), the standard lentiviral vector used for this study, RRLsin.hPGK.GFP.Wpre, was compared with the recently described cPPT-containing lentiviral construct, RRLsin.cPPT.hPGK.YFP.Wpre. 17 In both animals the lentiviral transgene EGFP was only detectable transiently at levels above 0.02% ( Figure 1a ). No expression of either the oncoretroviral transgene (in M99017) or the cPPT-lentiviral transgene (in J99202) was detectable for more than 1 month after transplantation. This was in contrast to the animals that received cells transduced in the presence of multiple recombinant growth factors (F97059, 00040, F98286, A00065): three of these four animals showed persistent gene marking and expression (Figure 1b) . Oncoretrovirally marked cells, however, declined rapidly after transplant in these animals ( Figure 1c ).
Engraftment kinetics of lentivirally transduced hematopoietic repopulating cells
In all animals that received cells transduced in the presence of growth factors, the percentage of peripheral blood cells expressing the oncoretroviral transgene EYFP was similar to or higher than the lentiviral transgene EGFP early after transplant (Figure 2a, b) . The average ratio of EGFP to EYFP-expressing cells was 0.76 after 12-18 days (n = 4). However, by 3 months after transplant, EGFPexpressing cells were on average 10-fold more abundant than EYFP-expressing cells (n = 3, animal F98286 died at day 35; Figures 2c and 3a) . Figure 3a shows the overall expression of EGFP and EYFP in animal F97059, which is the animal with the highest gene transfer rate and longest follow-up.
Interestingly, all four animals, after a short and transient initial decline, showed an increase over time in the percentage of cells expressing the lentiviral transgene (Figure 4a ). In three of the four animals, marked cells continued to increase to levels exceeding the initial marking level at about 1 month after transplant and has remained above the initial percentage for over 1 year now.
In contrast, the percentage of cells that expressed the oncoretrovirally introduced transgene declined over time (Figure 4b ). This has also been observed in previous and current studies with oncoretroviral vectors using transduction protocols which were optimized for oncoretroviral transduction. 13 In Figure 4c , we have included three animals from a separate study (manuscript in press) in which a PG13-derived oncoretroviral vector was used under conditions optimized for oncoretroviral transductions. All three animals received oncoretrovirally marked CD34-enriched marrow cells that were transduced using conditions which included a 48-h prestimulation with multiple cytokines and two subsequent vector exchanges over 24 h. Although gene transfer levels in these animals ranged between 2.4% and 3.0% at 100 days after transplant, this pattern of decrease of transgene-positive cells over time was persistent. In conclusion, these findings may suggest differential engraftment kinetics of lentivirally compared with oncoretrovirally transduced repopulating cells.
Dynamics of lentiviral expression in hematopoietic subpopulations
We followed transgene expression in CD13, CD3 and CD20 hematological subpopulations over time by flow cytometric analysis. Transgene expression of oncoretroviral vectors in different hematologic subpopulations has been described previously by us and by other groups. 18, 19 Here we show the time course of expression of a lentiviral transgene in different subpopulations over 10 months ( Figure 5 ). While the percentage of transgene-expressing granulocytes (CD13) and B cells (CD20) remains stable, there is a marked increase in the percentage of EGFP expressing T cells (CD3) over time. We also analyzed transgene expression in platelets and red blood cells and were able to detect up to 3% transgene-expressing platelets and up to 4% transgene-positive red blood cells, indicating multilineage repopulation by lentivirally transduced stem cells.
Decline in oncoretroviral transgene-expressing cells is not due to silencing
To exclude the possibility that the transgene in oncoretrovirally transduced cells was silenced, quantitative realGene Therapy time PCR on DNA extracted from peripheral blood leukocytes was performed in all animals. Figure 3b depicts results from animal F97059. As with expression monitored by flow cytometry, the persistence of the oncoretroviral transgene EYFP decreased to levels below our limit of detection (0.02%) after approximately 4 months. The lentiviral transgene EGFP was detectable at increasing levels, closely following the kinetics of gene expression as assessed by flow cytometry. The overall marking level as measured by PCR, however, was approximately threefold higher than gene expression at all time-points. Similar results were also obtained in other animals (data not shown). Marking levels were also assessed in hematopoietic subpopulations. CD13
+ granulocytes, CD3 + T cells and CD20
+ B cells were isolated by fluorescence-activated cell sorting (FACS). Similar to the results in peripheral blood cells, PCR-based marking levels were two-to three-fold higher than the percentage of gene-expressing cells in these hematopoietic subpopulations.
Discussion
In the current study we were able to demonstrate in a nonhuman primate model that stable multilineage engraftment of genetically modified cells was achieved after transduction of CD34-enriched marrow cells by lentiviral vectors using a relatively short transduction protocol of less than 2 days. We demonstrated that the presence of growth factors during lentiviral transduction allowed for efficient marking of hematopoietic repopulating cells. Furthermore, in contrast to the oncoretrovirally transduced cells, we observed that the percentage of lentivirally transduced cells increased over time, suggesting that a different hematopoietic repopulating cell may have been transduced.
Based on studies in hematopoietic progenitor cells and nonobese diabetic/severe combined immune-deficient (NOD/SCID) mice, 20 growth factor stimulation has not been considered necessary for transduction of hematopoietic stem cells by lentiviral vectors. In contrast to these findings, we did not observe persistent in vivo marking in baboons that received cells transduced in the absence of recombinant growth factors, even though gene transfer into hematopoietic progenitor cells before transplantation showed similar transduction rates between cells transduced in the presence or absence of growth factors. There are two likely explanations for this observation. Either long-term repopulating cells were not transduced, or the repopulating ability of CD34 + marrow cells was not maintained after a 2-day growth factor deprivation. Since the animal that received only lentivirally transduced cells (J99202) did not show any delayed engraftment, the repopulating ability of cells transduced by the lentivirus was probably maintained. These data therefore suggest that despite the ability of lentiviral vectors to integrate into non-dividing cells, 9 ,10 there appears to be a requirement for growth factor stimulation for efficient transduction of hematopoietic stem cells in large animal models. Low or absent lentiviral gene transfer into peripheral blood or marrow hematopoietic repopulating cells has recently also been reported by An et al 21, 22 in rhesus macaques. These findings in primate hematopoietic stem cells are in accordance with studies in lymphocytes which showed that resting T cells in G0 are not susceptible to productive infection by HIV. [23] [24] [25] More recent studies showed that activation of lymphocytes with cytokines led to efficient transduction of resting T cells without promoting their maturation or differentiation. 26 It is thus possible that quiescent hematopoietic stem cells in G0 are also resistant to transduction by lentiviral vectors, and that activation and transition from G0 to G1 is required for efficient transduction.
We have used a combination of recombinant growth factors (IL-3, IL-6, SCF, MGDF, Flt3-L, G-CSF) that has led to high-level gene marking of baboon hematopoietic repopulating cells using oncoretroviral vectors in a 3-day transduction protocol.
14 Employing this growth factor combination, we did not observe any persistence of oncoretrovirally transduced cells in the 2-day transduction protocol used in this study, suggesting that a 2-day cytokine stimulation was not sufficient for efficient oncoretroviral transduction. On the other hand, the transduction rate with the lentiviral vector in the animal with the highest marking levels (F97059) was similar to what we and others have previously reported using oncoretroviral vectors in longer transduction protocols. 8, 14, 15, 18, 27 It is, however, likely that different cytokine combinations or different cytokine concentrations are required for optimal transduction of hematopoietic stem cells by lentiviral vectors, since only cell activation and not cell division appears to be required for efficient lentiviral transduction.
Could the VSV-G-pseudotype have mediated better gene transfer than the GALV-pseudotype in our study? This is unlikely since the VSV-G-pseudotype oncoretroviral vector in animal A00065 did not result in increased gene marking. Furthermore, there is evidence from in vitro and in vivo studies that VSV-G-pseudotype oncoretroviral vectors do not perform better than GALVpseudotype or amphotropic vectors. [28] [29] [30] We observed an approximately three-fold difference between gene marking detected by PCR analysis and gene expression by flow cytometry for the lentiviral transgene. This difference could be due to silencing or integration site-dependent variegation of expression, or multiple transgene copies per cell. No progressive difference in marking frequencies was observed between FACS and PCR analysis, as would be expected with progressive silencing of the transgene. Also, the PCR to FACS ratio was very similar in all subpopulations. In light of the high MOIs used for the VSV-G-pseudotype lentiviral vector, the presence of multiple copies per cell is the most likely explanation and has been demonstrated using EPTS/LM-PCR technology described by Schmidt et al 31 (data not shown, manuscript submitted). The presence of multiple integration sites is very unlikely for oncoretrovi-ral stem cell transductions because the MOIs used for these transductions are usually around 1. In addition, previous clonal integration site analyses in both human NOD/SCID repopulating cells and in patients with adenosine deaminase deficiency showed that there was predominantly one oncoretroviral integration site per cell. 32, 33 While the percentage of oncoretrovirally transduced cells in peripheral blood after transplantation in this study decreased over time, the percentage of cells transduced with the lentiviral vector steadily increased over time in three out of four animals. This decrease in oncoretrovirally transduced cells was not only observed in this study using a relatively short 2-day transduction protocol, but more importantly, it was also seen in animals that received oncoretrovirally marked cells transduced under optimal conditions (Figure 4c) . 12, 13 The difference in engraftment kinetics was observed by flow cytometry and confirmed by PCR, indicating that these findings were not due to differential expression from the different promoters in the lentiviral and oncoretroviral vectors. These findings suggest that lentiviral vectors may transduce a different, possibly more immature hematopoietic repopulating cell than oncoretroviral vectors. The existence of HSC with differential repopulation potential has recently also been shown in NOD/SCID mice. 34 In conclusion, the findings presented here strongly suggest that lentiviral vectors are able to transduce early HSC and, thus, may provide a promising alternative vector system for clinical gene therapy applications involving hematopoietic stem cells.
Materials and methods
Retroviral and lentiviral vectors and vector production
The LYSN vector, based on the LXSN vector, 35 contains the yellow variant of the enhanced green fluorescent protein (EYFP) expressed from the retroviral LTR and the bacterial neomycin phosphotransferase (neo) gene expressed from the SV40 promoter. A stable PG13 retrovirus-producing cell clone with a titer of 3 × 10 5 infectious units/ml, as assessed by limiting dilution titering using EYFP, was chosen for all experiments.
The lentiviral transfer vector RRLsin.hPGK.GFP.Wpre (kindly provided by Cell Genesys, Foster City, CA, USA) is a self-inactivating, HIV-derived vector expressing the enhanced green fluorescent protein (EGFP) from the internal human phosphoglycerate kinase promotor (hPGK) containing a woodchuck hepatitis pre-element, and has been described previously. 36 In one animal we included the lentiviral vector RRLsin.cPPT.hPGK. YFP.Wpre (kindly provided by Dr L Naldini) which contains a central polypurine tract and expresses EYFP. 17 Vector stocks of VSV-G-pseudotype vectors (lentiviral and oncoretroviral vectors) were prepared by calcium phosphate-mediated three-plasmid transfection of 293T cells essentially as described. 37 Briefly, 27 g of the transfer vector construct, 17.5 g second generation gag-pol packaging construct pCMV.⌬R8.74 and 9.5 g VSV-G expression construct pMD.G were used for transfection of 12 × 10 6 293T cells overnight in 25 ml DMEM with 10% heat-inactivated fetal bovine serum. The cells were treated with 10 mM sodium butyrate during the first of three 12-h vector supernatant collections. The superGene Therapy natant was filtered through a 0.22-m pore-size filter and concentrated 100-fold by ultracentrifugation. All vector stocks were titered by transducing HT1080 cells using limiting dilutions of the stock with analysis for EGFP or EYFP expression by flow cytometry. The titers of the concentrated VSV-G-pseudotype vector preparations were between 3 × 10 7 and 1.4 × 10 9 infectious units/ml. 12, 13 Marrow was collected from the humeri and/or femora after 5 days of growth factor administration, rh-SCF (50 g/kg) and rh-G-CSF (100 g/kg) (kindly provided by Dr Graham Molineux, Amgen, Thousand Oaks, CA, USA). Marrow CD34
Gene transfer into baboon CD34-enriched cells
+ cells were enriched as described. 12, 13 The purity of CD34-enriched cells from baboon bone marrow averaged 83% (range 75% to 92%). Equal numbers of CD34-enriched cells were placed into non-tissue-culture-treated 75-cm 2 canted-neck flasks (Becton Dickinson, Franklin Lake, NJ, USA) at 5-10 × 10 6 cells/flask that had been coated with CH-296 (RetroNectin, generously provided by Takara Shuzo, Japan) at 2 g/cm 2 as described. 38 Cells were prestimulated for 18 h in Iscove's modified Dulbecco medium (IMDM) supplemented with 12.5% horse serum (GIBCO-BRL), 12.5% FBS (Hyclone, Logan, UT, USA), 10 -6 M hydrocortisone (Sigma Chemical, St Louis, MO, USA), 10 -4 M 2-mercaptoethanol (Sigma), 1% glutamine, 1% penicillin/ streptomycin (GIBCO-BRL) in the presence or absence of multiple recombinant human growth factors (IL-3, IL-6, SCF, MGDF, Flt3-L, G-CSF) at 100 ng/ml each, and then transduced on CH-296 twice within 24 h, again in the presence or absence of the described growth factors (see Table 1 ). Transductions were performed in the presence of 8 g/ml protamine sulfate at an MOI of 20-150 for the VSV-G-pseudotype vectors and approximately 1 for the GALV-pseudotype vector. After transduction, nonadherent and adherent cells were pooled, counted and infused intravenously into the irradiated animals. All animals received myeloablative doses (1020 cGy) of total body irradiation (TBI) administered from opposing 60 Co sources at 7 cGy/min as two equal divided doses 24 h apart. Animals in the present study were given 100 g/kg G-CSF intravenously after transplant, once daily starting at day 0 until their peripheral blood neutrophil counts were >500/l.
Flow cytometric analysis and sorting EGFP
+ or EYFP + cells were quantified by flow cytometric analysis of typically 500 000 events (propidium iodide (2 g/ml)-excluding, forward and right-angle light scattergated) on a FACS Vantage (Becton Dickinson, San Jose, CA, USA). Analysis of flow cytometric data was performed using CELLQuest v3.3 software. Murine anti-human monoclonal antibodies conjugated to phycoerythrin (PE) which had been shown to bind baboon CD markers included: anti-CD13 (clone L138), anti-CD20 (clone L27), and matched control (clone X40), which were all obtained from Becton Dickinson. Anti-CD3 (clone FN-18) was obtained from BioSource International (Camarillo, CA, USA). All subset sorts were performed on a FACS Vantage using identical cell staining and sorting conditions as described above.
CFU-C assay CD34-enriched cells (1000 per 35-mm plate) were cultured in triplicate in a double-layer agar culture system as previously described. 12 Untransduced control cells were plated simultaneously. Cultures were incubated at 37°C in a 5% CO 2 humidified incubator. Colonies were enumerated at day 14. One hundred single colonies per transduction condition were picked, and DNA was extracted from colonies for PCR as described. 12 TaqMan real-time PCR assay Relative marking levels with EGFP and EYFP were analyzed with the TaqMan 5' nuclease quantitative real-time PCR assay. 39 Genomic DNA from marrow and peripheral blood leukocytes was prepared using proteinase K (Sigma, St Louis, MO, USA) followed by ethanol precipitation or using the Qiagen DNA Blood columns (Qiagen, Valencia, CA, USA). For the analysis of myeloid and lymphocyte subpopulations, granulocytes, T cells and B cells were sorted using CD13, CD3 and CD20 antibodies. Collected cell pellets underwent DNA extraction and PCR under conditions described below. Calculated gene transfer percentages assume that the marrow and peripheral blood cells contain one copy of the corresponding vector per cell.
Three hundred ng of DNA was amplified in duplicate with an EGFP-specific primer/probe combination (5'-CTG CAC CAC CGG CAA-3' and 5'-GTA GCG GCT GAA GCA CTG-3', probe: 5'-FAM-CCA CCC TGA CCT ACG GCG TG-TAMRA-3'; Synthegen, Houston, TX, USA), with an EYFP-specific primer/probe combination (5'-CTG CAC CAC CGG CAA-3' and 5'-GTA GCG GGC GAA GCA CT-3', probe: 5'-FAM-CCA CCT TCG GCT ACG GCC TG -TAMRA-3'), and a beta-globin specific primer/probe combination (5'-CCT ATC AGA AAG TGG TGG CTG G-3', 5'-TTG GAC AGC AAG AAA GTG AGC TT-3', probe 5'-FAM-TGG CTA ATG CCC TGG CCC ACA AGT A-TAMRA-3'). Standards consisted of dilutions of DNA extracted from cell lines transduced with a single copy of the EGFP or EYFP vector. Reactions were run using the ABI master mix (Applied Biosystems, Branchburg, NJ, USA) on the ABI Prism 7700 sequence detection system (Applied Biosystems) using the following thermal cycling conditions: 50°C for 2 min and 95°C for 10 min, then 40 cycles of 95°C for 15 s and 60°C for 1 min.
Detection of helper virus
At up to three time-points after transplantation, peripheral blood mononuclear cell DNA was assayed for recombinant helper virus genomes by PCR using the primers and PCR conditions described previously. 12 PCR analysis of peripheral blood samples for the presence of GALV envelope sequences was negative in all animals indicating the absence of helper-virus infection. The presence of recombinant replication competent lentiviral vectors in the serum of transplanted baboons was analyzed by the p24 Antigen Assay (Beckman Coulter, Miami, FL, USA) according to the manufacturer's recommendations.
